Immediate Impact
1 from Science/Nature 37 hit
Citing Papers
Management of chronic myeloid leukemia in 2023 – common ground and common sense
2023 Hit
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
2023 Hit
Works of Susan O’Brien being referenced
Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium
2014
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
2012